Tremelimumab, Durvalumab, and Belinostat for the Treatment of ARID1A Mutated Metastatic or Unresectable, Locally Advanced Urothelial Carcinoma (RESOLVE)

  • End date
    Nov 30, 2025
  • participants needed
  • sponsor
    University of Utah
Updated on 25 May 2022


This phase I trial studies the side effects and best dose of belinostat when given together with tremelimumab and durvalumab in treating patients with urothelial cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and has spread to nearby tissue or lymph nodes (locally advanced). Immunotherapy with monoclonal antibodies, such as tremelimumab and durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Belinostat is a potential anti-cancer drug, known as a histone deacetylase (HDAC) inhibitor, which means that belinostat stops the activity of HDAC enzymes (an enzyme is a protein that in small amounts can speed up a biological reaction). HDAC enzymes play an important role in cell growth and cell death. Giving tremelimumab, durvalumab, and belinostat may improve the body's ability to fight cancer.



I. To assess the recommended phase 2 dose of belinostat in combination with tremelimumab and durvalumab in advanced solid tumors harboring ARID1A mutations with focus on urothelial carcinoma. (Phase 1A) II. To assess the ongoing safety of belinostat in combination with tremelimumab and durvalumab in patients with advanced solid tumors with ARID1A mutation with focus on urothelial cancer. (Phase 1B)


I. To assess the efficacy of belinostat in combination with tremelimumab and durvalumab in patients with advanced urothelial cancer with ARID1A mutation.


I. To assess the mechanism of action of belinostat in combination with tremelimumab and durvalumab.

II. To explore possible mechanisms of treatment resistance. III. To explore possible biomarkers predictive of treatment benefit.

OUTLINE: This is a dose-escalation study of belinostat.

Patients receive durvalumab intravenously (IV) over 30 minutes on day 1. Patients also receive tremelimumab IV over 60 minutes on day 1 of cycle 1. Beginning cycle 2, patients receive belinostat IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 7 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 1 year and then every 6 months for 2 years.

Condition Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Treatment tremelimumab, durvalumab, Belinostat
Clinical Study IdentifierNCT05154994
SponsorUniversity of Utah
Last Modified on25 May 2022


Yes No Not Sure

Inclusion Criteria

Male or female subject aged >= 18 years
Histologically confirmed urothelial carcinoma with metastatic disease or with unresectable, locally advanced disease. Variant histology, including, but not limited to, neuroendocrine, sarcomatoid, and squamous differentiation are permitted to enroll
Patients must meet one or more of the following criteria
Has progressed on at least one prior therapy; or
Has declined standard therapy; or
Is not a suitable candidate for standard therapy
The discussion regarding the choice of standard therapy offered, if available, and patient's choice and reason(s) to decline standard therapy should be documented clearly in the research chart
Patients may have progressed on immune checkpoint inhibitor therapy
Body weight > 30 kg
Malignancy harboring ARID1A loss of function (lof) genomic alterations as determined by the standard of care next-generation sequencing. Results must meet the following
Presence of a somatic alteration considered pathogenic/likely pathogenic in ARID1A gene as determined by genomic sequencing performed in a Clinical Laboratory Improvement Amendments (CLIA) laboratory
Somatic alterations will include nonsense, frameshift, splice-site or missense mutations or gene deletions
Subject must have measurable disease by Response Evaluation Criteria in Solid Tumors
(RECIST) 1.1 criteria by computed tomography (CT) or magnetic resonance
imaging (MRI)
Eastern Cooperative Oncology Group (ECOG) performance status =< 1
Absolute neutrophil count (ANC) >= 1500/mm^3
Platelet count >= 100,000/mm^3
Hemoglobin >= 10 g/dL
Total Bilirubin =< 1.5 x institutional upper limit of normal (ULN)
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN
Patients with liver metastases will be allowed to enroll with AST and ALT levels =< 5 x ULN
Estimated creatinine clearance >= 30 mL/min by Cockcroft-Gault formula
Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply
Women < 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy)
Women >= 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses > 1 year ago, had chemotherapy-induced menopause with last menses > 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy)
Highly effective contraception for both male and female subjects throughout the study
and at least 4 months after last study treatment administration
Recovery to baseline or =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 from toxicities related to any prior treatments, unless adverse event (AE)(s) are clinically non-significant and/or stable on supportive therapy
Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines
Estimated life expectancy of at least 12 weeks

Exclusion Criteria

Homozygous for UGT1A128 allele or Gilbert syndrome
Subject has received systemic antineoplastic therapy (including unconjugated therapeutic antibodies and toxin immunoconjugates) or any investigational therapy =< 14 days or within 5 half-lives before starting study treatment, whichever is shorter
Prior treatment with durvalumab plus tremelimumab
Subject has received radiotherapy =< 14 days before the first dose of study treatment. Localized radiation therapy for the treatment of symptomatic bone metastasis is allowed during that timeframe
Subjects who have undergone major surgery =< 3 weeks before starting study drug or who have not fully recovered from major surgery
Diagnosis of any other malignancy within 2 years before study enrollment, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the breast, bladder or of the cervix, and prostate cancer on surveillance with no plans for treatment intervention (e.g., surgery, radiation, or castration) or prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease or symptoms is allowed
Known brain metastases or cranial epidural disease
Note: Brain metastases or cranial epidural disease adequately treated with radiotherapy and/or surgery and stable for at least 4 weeks before the first dose of study treatment will be allowed on trial. Subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the first dose of study treatment
Current evidence of uncontrolled, clinically significant intercurrent illness
including, but not limited to, the following conditions
Cardiovascular disorders
Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias
Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or other ischemic events, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 3 months before the first dose
Uncontrolled hypertension defined as a sustained systolic blood pressure >= 160 mmHg or a diastolic blood pressure >= 100 mmHg despite optimal management
Note: Patients with uncontrolled hypertension who are not optimally managed may be rescreened once controlled hypertension is achieved
Patients with uncorrectable prolonged corrected QT (QTc) (Bezet formula) >
msec or concomitant use of medications(s) with a known risk of inducing
Torsade de Pointes if such treatment cannot be discontinued or switched to a
different medication before starting the study drug
Note: If a single electrocardiogram (ECG) shows a QTc with an absolute value > 480 msec, two additional ECGs approximately 2 minutes apart must be performed within 30 minutes of the initial ECG, and the average of these three consecutive results for QTc will be used
Adrenal insufficiency
Interstitial lung disease (ILD)
Subjects with congenital long QT syndrome
Patients currently on or who will require valproic acid for any medical condition during the study
Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [except for diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion
Patients with vitiligo or alopecia
Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
Any chronic skin condition that does not require systemic therapy
Patients without active disease in the last 5 years may be included but only after consultation with the principal investigator
Patients with celiac disease controlled by diet alone
Current or prior use of immunosuppressive medication within 14 days of cycle one day
one, EXCEPT for the following permitted steroids
Intranasal, inhaled, topical steroids, eye drops or local steroid injection (e.g., intra-articular injection)
Systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent
Steroids as premedication for hypersensitivity reactions (e.g., computed tomography (CT) scan premedication)
History of active primary immunodeficiency
Known human immunodeficiency virus (HIV) infection with a detectable viral load at the time of screening
Note: Patients on effective antiretroviral therapy with an undetectable viral load at the time of screening are eligible for this trial
Active infection including tuberculosis (clinical evaluation that includes clinical
history, physical examination, and radiographic findings, and tuberculosis
(TB) testing in line with local practice), hepatitis B (known positive
hepatitis B virus [HBV] surface antigen (HBsAg) result), or hepatitis C
Note: Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA)
Live attenuated vaccinations within 4 weeks of cycle one day one and while on trial is
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] CTCAE version [v]5.0 grade >= 3)
Subjects taking prohibited medications. A washout period of prohibited medications for a period of at least 5 half-lives or as clinically indicated should occur before the start of treatment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note